Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 43 entries
Sorted by: Best Match Show Resources per page
The ability of early changes in motivation to predict later antidepressant treatment response.

Neuropsychiatric disease and treatment

Gorwood P, Vaiva G, Corruble E, Llorca PM, Baylé FJ, Courtet P.
PMID: 26635476
Neuropsychiatr Dis Treat. 2015 Nov 11;11:2875-82. doi: 10.2147/NDT.S92795. eCollection 2015.

INTRODUCTION: Baseline values and early changes of emotional reactivity, cognitive speed, psychomotor function, motivation, and sensory perception have not been studied to any extent in unipolar depression, although they could help to characterize different dimensions of illness that are...

Cite
Gorwood P, Vaiva G, Corruble E, et al. The ability of early changes in motivation to predict later antidepressant treatment response. Neuropsychiatr Dis Treat. 2015;11:2875-82doi: 10.2147/NDT.S92795.
Gorwood, P., Vaiva, G., Corruble, E., Llorca, P. M., Baylé, F. J., & Courtet, P. (2015). The ability of early changes in motivation to predict later antidepressant treatment response. Neuropsychiatric disease and treatment, 112875-82. https://doi.org/10.2147/NDT.S92795
Gorwood, Philip, et al. "The ability of early changes in motivation to predict later antidepressant treatment response." Neuropsychiatric disease and treatment vol. 11 (2015): 2875-82. doi: https://doi.org/10.2147/NDT.S92795
Gorwood P, Vaiva G, Corruble E, Llorca PM, Baylé FJ, Courtet P. The ability of early changes in motivation to predict later antidepressant treatment response. Neuropsychiatr Dis Treat. 2015 Nov 11;11:2875-82. doi: 10.2147/NDT.S92795. eCollection 2015. PMID: 26635476; PMCID: PMC4646593.
Copy Download .nbib Format: NLM
[What strategy can be developed by a regional health agency to reduce social inequalities in health?].

Sante publique (Vandoeuvre-les-Nancy, France)

Coruble G, Sauze L, Riff H.
PMID: 25490221
Sante Publique. 2014 Sep-Oct;26(5):621-5.

Reducing social inequalities in health (SIH) is a key priority for the Provence Alpes Côte d'Azur Regional Health Agency (Paca ARS). The actions and objectives defined in the regional health project were divided into a two-way table (determinants/policies by...

Cite
Coruble G, Sauze L, Riff H. Quelle stratégie peut développer une Agence régionale de santé pour réduire les inégalités sociales de santé?? [What strategy can be developed by a regional health agency to reduce social inequalities in health?]. Sante Publique. 2014;26(5):621-5
Coruble, G., Sauze, L., & Riff, H. (2014). Quelle stratégie peut développer une Agence régionale de santé pour réduire les inégalités sociales de santé?? [What strategy can be developed by a regional health agency to reduce social inequalities in health?]. Sante publique (Vandoeuvre-les-Nancy, France), 26(5), 621-5.
Coruble, Gérard, et al. "Quelle stratégie peut développer une Agence régionale de santé pour réduire les inégalités sociales de santé??" [What strategy can be developed by a regional health agency to reduce social inequalities in health?]. Sante publique (Vandoeuvre-les-Nancy, France) vol. 26,5 (2014): 621-5.
Coruble G, Sauze L, Riff H. Quelle stratégie peut développer une Agence régionale de santé pour réduire les inégalités sociales de santé?? [What strategy can be developed by a regional health agency to reduce social inequalities in health?]. Sante Publique. 2014 Sep-Oct;26(5):621-5. French. PMID: 25490221.
Copy Download .nbib Format: NLM
Use of potentially driver-impairing drugs among older drivers.

BMC geriatrics

Zitoun S, Baudouin E, Corruble E, Vidal JS, Becquemont L, Duron E.
PMID: 34979970
BMC Geriatr. 2022 Jan 03;22(1):4. doi: 10.1186/s12877-021-02726-5.

BACKGROUND: Road safety is a major issue among seniors. Potentially Driver-Impairing (PDI) drugs are known to increase the risk of car accident. The aim of this cross-sectional study was to describe PDI-drug consumption among older drivers and determine associated...

Cite
Zitoun S, Baudouin E, Corruble E, et al. Use of potentially driver-impairing drugs among older drivers. BMC Geriatr. 2022;22(1):4doi: 10.1186/s12877-021-02726-5.
Zitoun, S., Baudouin, E., Corruble, E., Vidal, J. S., Becquemont, L., & Duron, E. (2022). Use of potentially driver-impairing drugs among older drivers. BMC geriatrics, 22(1), 4. https://doi.org/10.1186/s12877-021-02726-5
Zitoun, Sarah, et al. "Use of potentially driver-impairing drugs among older drivers." BMC geriatrics vol. 22,1 (2022): 4. doi: https://doi.org/10.1186/s12877-021-02726-5
Zitoun S, Baudouin E, Corruble E, Vidal JS, Becquemont L, Duron E. Use of potentially driver-impairing drugs among older drivers. BMC Geriatr. 2022 Jan 03;22(1):4. doi: 10.1186/s12877-021-02726-5. PMID: 34979970; PMCID: PMC8722131.
Copy Download .nbib Format: NLM
The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.

Journal of affective disorders

Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C.
PMID: 34906639
J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11.

BACKGROUND: Pharmacological studies have yielded valuable insights into the role of the serotonin 4 receptor (HTR4) in major depressive episodes (MDE) and response to antidepressant drugs (AD). A genetic association has been shown between HTR4 and susceptibility to mood...

Cite
Poinsignon V, Colle R, Asmar KE, et al. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021;299:335-343doi: 10.1016/j.jad.2021.12.012.
Poinsignon, V., Colle, R., Asmar, K. E., Mendez-David, I., David, D. J., Ait Tayeb, A. E. K., Chappell, K., Gressier, F., Herrero, H., Fève, B., Becquemont, L., Corruble, E., & Verstuyft, C. (2021). The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. Journal of affective disorders, 299335-343. https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon, Vianney, et al. "The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort." Journal of affective disorders vol. 299 (2021): 335-343. doi: https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11. PMID: 34906639.
Copy Download .nbib Format: NLM
Reviving through human hippocampal newborn neurons.

L'Encephale

Mendez-David I, Schofield R, Tritschler L, Colle R, Guilloux JP, Gardier AM, Corruble E, Hen R, David DJ.
PMID: 34649711
Encephale. 2021 Oct 11; doi: 10.1016/j.encep.2021.09.001. Epub 2021 Oct 11.

Recent contradictory data has renewed discussion regarding the existence of adult hippocampal neurogenesis (AHN) in humans, i.e., the continued production of new neurons in the brain after birth. The present review revisits the debate of AHN in humans from...

Cite
Mendez-David I, Schofield R, Tritschler L, et al. Reviving through human hippocampal newborn neurons. Encephale. 2021;doi: 10.1016/j.encep.2021.09.001.
Mendez-David, I., Schofield, R., Tritschler, L., Colle, R., Guilloux, J. P., Gardier, A. M., Corruble, E., Hen, R., & David, D. J. (2021). Reviving through human hippocampal newborn neurons. L'Encephale, . https://doi.org/10.1016/j.encep.2021.09.001
Mendez-David, I, et al. "Reviving through human hippocampal newborn neurons." L'Encephale vol. (2021). doi: https://doi.org/10.1016/j.encep.2021.09.001
Mendez-David I, Schofield R, Tritschler L, Colle R, Guilloux JP, Gardier AM, Corruble E, Hen R, David DJ. Reviving through human hippocampal newborn neurons. Encephale. 2021 Oct 11; doi: 10.1016/j.encep.2021.09.001. Epub 2021 Oct 11. PMID: 34649711.
Copy Download .nbib Format: NLM
The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.

Journal of affective disorders

Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C.
PMID: 34906639
J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11.

BACKGROUND: Pharmacological studies have yielded valuable insights into the role of the serotonin 4 receptor (HTR4) in major depressive episodes (MDE) and response to antidepressant drugs (AD). A genetic association has been shown between HTR4 and susceptibility to mood...

Cite
Poinsignon V, Colle R, Asmar KE, et al. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021;299:335-343doi: 10.1016/j.jad.2021.12.012.
Poinsignon, V., Colle, R., Asmar, K. E., Mendez-David, I., David, D. J., Ait Tayeb, A. E. K., Chappell, K., Gressier, F., Herrero, H., Fève, B., Becquemont, L., Corruble, E., & Verstuyft, C. (2021). The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. Journal of affective disorders, 299335-343. https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon, Vianney, et al. "The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort." Journal of affective disorders vol. 299 (2021): 335-343. doi: https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11. PMID: 34906639.
Copy Download .nbib Format: NLM
The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.

Journal of affective disorders

Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C.
PMID: 34906639
J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11.

BACKGROUND: Pharmacological studies have yielded valuable insights into the role of the serotonin 4 receptor (HTR4) in major depressive episodes (MDE) and response to antidepressant drugs (AD). A genetic association has been shown between HTR4 and susceptibility to mood...

Cite
Poinsignon V, Colle R, Asmar KE, et al. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021;299:335-343doi: 10.1016/j.jad.2021.12.012.
Poinsignon, V., Colle, R., Asmar, K. E., Mendez-David, I., David, D. J., Ait Tayeb, A. E. K., Chappell, K., Gressier, F., Herrero, H., Fève, B., Becquemont, L., Corruble, E., & Verstuyft, C. (2021). The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. Journal of affective disorders, 299335-343. https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon, Vianney, et al. "The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort." Journal of affective disorders vol. 299 (2021): 335-343. doi: https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11. PMID: 34906639.
Copy Download .nbib Format: NLM
The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.

Journal of affective disorders

Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C.
PMID: 34906639
J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11.

BACKGROUND: Pharmacological studies have yielded valuable insights into the role of the serotonin 4 receptor (HTR4) in major depressive episodes (MDE) and response to antidepressant drugs (AD). A genetic association has been shown between HTR4 and susceptibility to mood...

Cite
Poinsignon V, Colle R, Asmar KE, et al. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021;299:335-343doi: 10.1016/j.jad.2021.12.012.
Poinsignon, V., Colle, R., Asmar, K. E., Mendez-David, I., David, D. J., Ait Tayeb, A. E. K., Chappell, K., Gressier, F., Herrero, H., Fève, B., Becquemont, L., Corruble, E., & Verstuyft, C. (2021). The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. Journal of affective disorders, 299335-343. https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon, Vianney, et al. "The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort." Journal of affective disorders vol. 299 (2021): 335-343. doi: https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11. PMID: 34906639.
Copy Download .nbib Format: NLM
Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients.

Expert opinion on pharmacotherapy

Mouaffak F, Ferreri F, Bourgin-Duchesnay J, Baloche E, Blin O, Vandel P, Garay RP, Vidailhet P, Corruble E, Llorca PM.
PMID: 34338130
Expert Opin Pharmacother. 2021 Dec;22(18):2507-2519. doi: 10.1080/14656566.2021.1958781. Epub 2021 Aug 17.

Antipsychotic (AP) dosing is well established in nonelderly patients with acute exacerbations of schizophrenia, but not in special populations.This review describes the AP dosing procedures that have been used in clinical studies for acute psychotic agitation, a first episode...

Cite
Mouaffak F, Ferreri F, Bourgin-Duchesnay J, et al. Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. Expert Opin Pharmacother. 2021;22(18):2507-2519doi: 10.1080/14656566.2021.1958781.
Mouaffak, F., Ferreri, F., Bourgin-Duchesnay, J., Baloche, E., Blin, O., Vandel, P., Garay, R. P., Vidailhet, P., Corruble, E., & Llorca, P. M. (2021). Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. Expert opinion on pharmacotherapy, 22(18), 2507-2519. https://doi.org/10.1080/14656566.2021.1958781
Mouaffak, Fayçal, et al. "Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients." Expert opinion on pharmacotherapy vol. 22,18 (2021): 2507-2519. doi: https://doi.org/10.1080/14656566.2021.1958781
Mouaffak F, Ferreri F, Bourgin-Duchesnay J, Baloche E, Blin O, Vandel P, Garay RP, Vidailhet P, Corruble E, Llorca PM. Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients. Expert Opin Pharmacother. 2021 Dec;22(18):2507-2519. doi: 10.1080/14656566.2021.1958781. Epub 2021 Aug 17. PMID: 34338130.
Copy Download .nbib Format: NLM
The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort.

Journal of affective disorders

Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C.
PMID: 34906639
J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11.

BACKGROUND: Pharmacological studies have yielded valuable insights into the role of the serotonin 4 receptor (HTR4) in major depressive episodes (MDE) and response to antidepressant drugs (AD). A genetic association has been shown between HTR4 and susceptibility to mood...

Cite
Poinsignon V, Colle R, Asmar KE, et al. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021;299:335-343doi: 10.1016/j.jad.2021.12.012.
Poinsignon, V., Colle, R., Asmar, K. E., Mendez-David, I., David, D. J., Ait Tayeb, A. E. K., Chappell, K., Gressier, F., Herrero, H., Fève, B., Becquemont, L., Corruble, E., & Verstuyft, C. (2021). The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. Journal of affective disorders, 299335-343. https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon, Vianney, et al. "The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort." Journal of affective disorders vol. 299 (2021): 335-343. doi: https://doi.org/10.1016/j.jad.2021.12.012
Poinsignon V, Colle R, Asmar KE, Mendez-David I, David DJ, Ait Tayeb AEK, Chappell K, Gressier F, Herrero H, Fève B, Becquemont L, Corruble E, Verstuyft C. The GG genotype of the serotonin 4 receptor genetic polymorphism, rs1345697, is associated with lower remission rates after antidepressant treatment: Findings from the METADAP cohort. J Affect Disord. 2021 Dec 11;299:335-343. doi: 10.1016/j.jad.2021.12.012. Epub 2021 Dec 11. PMID: 34906639.
Copy Download .nbib Format: NLM
Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort.

World psychiatry : official journal of the World Psychiatric Association (WPA)

Corruble E, El Asmar K, Trabado S, Verstuyft C, Falissard B, Colle R, Petit AC, Gressier F, Brailly-Tabard S, Ferreri F, Lépine JP, Haffen E, Polosan M, Bourrier C, Perlemuter G, Chanson P, Fève B, Becquemont L.
PMID: 26407797
World Psychiatry. 2015 Oct;14(3):366-7. doi: 10.1002/wps.20260.

No abstract available.

Cite
Corruble E, El Asmar K, Trabado S, et al. Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort. World Psychiatry. 2015;14(3):366-7doi: 10.1002/wps.20260.
Corruble, E., El Asmar, K., Trabado, S., Verstuyft, C., Falissard, B., Colle, R., Petit, A. C., Gressier, F., Brailly-Tabard, S., Ferreri, F., Lépine, J. P., Haffen, E., Polosan, M., Bourrier, C., Perlemuter, G., Chanson, P., Fève, B., & Becquemont, L. (2015). Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort. World psychiatry : official journal of the World Psychiatric Association (WPA), 14(3), 366-7. https://doi.org/10.1002/wps.20260
Corruble, Emmanuelle, et al. "Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort." World psychiatry : official journal of the World Psychiatric Association (WPA) vol. 14,3 (2015): 366-7. doi: https://doi.org/10.1002/wps.20260
Corruble E, El Asmar K, Trabado S, Verstuyft C, Falissard B, Colle R, Petit AC, Gressier F, Brailly-Tabard S, Ferreri F, Lépine JP, Haffen E, Polosan M, Bourrier C, Perlemuter G, Chanson P, Fève B, Becquemont L. Treating major depressive episodes with antidepressants can induce or worsen metabolic syndrome: results of the METADAP cohort. World Psychiatry. 2015 Oct;14(3):366-7. doi: 10.1002/wps.20260. PMID: 26407797; PMCID: PMC4592664.
Copy Download .nbib Format: NLM
Methodological issues raised by clinical trials on dysthymia: assessment instruments and response criteria.

European psychiatry : the journal of the Association of European Psychiatrists

Guelfi JD, Corruble E.
PMID: 19698529
Eur Psychiatry. 1997;12(4):183-9. doi: 10.1016/S0924-9338(97)89102-X.

Dysthymia clinical trials raise several methodological issues. The validity of the concept remains a matter of concern, as does the need for specific instruments, the difficulties in assessment of change and long-term assessments. Diagnostic criteria for inclusion should be...

Cite
Guelfi JD, Corruble E. Methodological issues raised by clinical trials on dysthymia: assessment instruments and response criteria. Eur Psychiatry. 1997;12(4):183-9doi: 10.1016/S0924-9338(97)89102-X.
Guelfi, J. D., & Corruble, E. (1997). Methodological issues raised by clinical trials on dysthymia: assessment instruments and response criteria. European psychiatry : the journal of the Association of European Psychiatrists, 12(4), 183-9. https://doi.org/10.1016/S0924-9338(97)89102-X
Guelfi, J D, and Corruble, E. "Methodological issues raised by clinical trials on dysthymia: assessment instruments and response criteria." European psychiatry : the journal of the Association of European Psychiatrists vol. 12,4 (1997): 183-9. doi: https://doi.org/10.1016/S0924-9338(97)89102-X
Guelfi JD, Corruble E. Methodological issues raised by clinical trials on dysthymia: assessment instruments and response criteria. Eur Psychiatry. 1997;12(4):183-9. doi: 10.1016/S0924-9338(97)89102-X. PMID: 19698529.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 43 entries